215 related articles for article (PubMed ID: 28391912)
1. Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A5275).
Nixon DE; Bosch RJ; Chan ES; Funderburg NT; Hodder S; Lake JE; Lederman MM; Klingman KL; Aberg JA;
J Clin Lipidol; 2017; 11(1):61-69. PubMed ID: 28391912
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the effect of atorvastatin exposure and vitamin D levels on lipid outcomes in people with HIV-1 with suppressed HIV-1 RNA and LDL cholesterol <130 mg/dL.
Rahman F; Brates I; Aweeka F; Bosch RJ; Deitchman A; Nixon D; Aberg JA
HIV Med; 2023 Jun; 24(6):749-753. PubMed ID: 36549898
[TBL] [Abstract][Full Text] [Related]
3. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial.
Ganesan A; Crum-Cianflone N; Higgins J; Qin J; Rehm C; Metcalf J; Brandt C; Vita J; Decker CF; Sklar P; Bavaro M; Tasker S; Follmann D; Maldarelli F
J Infect Dis; 2011 Mar; 203(6):756-64. PubMed ID: 21325137
[TBL] [Abstract][Full Text] [Related]
4. Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy.
Eckard AR; Jiang Y; Debanne SM; Funderburg NT; McComsey GA
J Infect Dis; 2014 Apr; 209(8):1156-64. PubMed ID: 24415784
[TBL] [Abstract][Full Text] [Related]
5. Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study.
Di Yacovo S; Saumoy M; Sánchez-Quesada JL; Navarro A; Sviridov D; Javaloyas M; Vila R; Vernet A; Low H; Peñafiel J; García B; Ordoñez-Llanos J; Podzamczer D
PLoS One; 2020; 15(8):e0237739. PubMed ID: 32817629
[TBL] [Abstract][Full Text] [Related]
6. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
[TBL] [Abstract][Full Text] [Related]
7. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
[TBL] [Abstract][Full Text] [Related]
8. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
[TBL] [Abstract][Full Text] [Related]
9. Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals.
Longenecker CT; Funderburg NT; Jiang Y; Debanne S; Storer N; Labbato DE; Lederman MM; McComsey GA
HIV Med; 2013 Jul; 14(6):385-90. PubMed ID: 23332012
[TBL] [Abstract][Full Text] [Related]
10. A Randomized, Double-blinded, Placebo-controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed Human Immunodeficiency Virus Infection.
Dubé MP; Chan ES; Lake JE; Williams B; Kinslow J; Landay A; Coombs RW; Floris-Moore M; Ribaudo HJ; Yarasheski KE
Clin Infect Dis; 2019 Sep; 69(7):1165-1172. PubMed ID: 30535188
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of fixed dose combination of atorvastatin and hydroxychloroquine: a randomized, double-blind comparison with atorvastatin alone among Indian patients with dyslipidemia.
Pareek A; Chandurkar N; Thulaseedharan NK; Legha R; Agarwal M; Mathur SL; Salkar HR; Pednekar S; Pai V; Sriram U; Khyalappa R; Parmar M; Agrawal N; Dhruv U; Saxena S
Curr Med Res Opin; 2015 Nov; 31(11):2105-17. PubMed ID: 26371518
[TBL] [Abstract][Full Text] [Related]
12. Monocyte-activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection.
Wilson EM; Singh A; Hullsiek KH; Gibson D; Henry WK; Lichtenstein K; Önen NF; Kojic E; Patel P; Brooks JT; Sereti I; Baker JV;
J Infect Dis; 2014 Nov; 210(9):1396-406. PubMed ID: 24813472
[TBL] [Abstract][Full Text] [Related]
13. HIV and cardiovascular diseases risk: exploring the interplay between T-cell activation, coagulation, monocyte subsets, and lipid subclass alterations.
Teer E; Joseph DE; Driescher N; Nell TA; Dominick L; Midgley N; Deshpande G; Page MJ; Pretorius E; Woudberg NJ; Lecour S; Glashoff RH; Essop MF
Am J Physiol Heart Circ Physiol; 2019 May; 316(5):H1146-H1157. PubMed ID: 30768357
[TBL] [Abstract][Full Text] [Related]
14. LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy.
Saumoy M; Sánchez-Quesada JL; Martínez E; Llibre JM; Ribera E; Knobel H; Gatell JM; Clotet B; Curran A; Curto J; Masó M; Ordoñez-Llanos J; Podzamczer D
Atherosclerosis; 2012 Nov; 225(1):200-7. PubMed ID: 23017355
[TBL] [Abstract][Full Text] [Related]
15. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.
Martínez E; Larrousse M; Podzamczer D; Pérez I; Gutiérrez F; Loncá M; Barragán P; Deulofeu R; Casamitjana R; Mallolas J; Pich J; Gatell JM;
AIDS; 2010 Jan; 24(3):F1-9. PubMed ID: 20009917
[TBL] [Abstract][Full Text] [Related]
16. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir.
Martínez E; D'Albuquerque PM; Llibre JM; Gutierrez F; Podzamczer D; Antela A; Berenguer J; Domingo P; Moreno X; Perez I; Pich J; Gatell JM;
AIDS; 2012 Nov; 26(18):2315-26. PubMed ID: 23018438
[TBL] [Abstract][Full Text] [Related]
17. Effect of atorvastatin on subclinical atherosclerosis in virally-suppressed HIV-infected patients with CMV seropositivity: a randomized double-blind placebo-controlled trial.
Yunihastuti E; Rusdi L; Syahrir Azizi M; Estiasari R; Jasirwan COM; Wulandari EAT; Purnamasari D; Shinta Noviar M; Aman Nasution S
F1000Res; 2021; 10():151. PubMed ID: 37772075
[No Abstract] [Full Text] [Related]
18. Serum oxidized low-density lipoprotein decreases in response to statin therapy and relates independently to reductions in coronary plaque in patients with HIV.
Nou E; Lu MT; Looby SE; Fitch KV; Kim EA; Lee H; Hoffmann U; Grinspoon SK; Lo J
AIDS; 2016 Feb; 30(4):583-90. PubMed ID: 26558731
[TBL] [Abstract][Full Text] [Related]
19. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
20. Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
Kelesidis T; Tran TT; Stein JH; Brown TT; Moser C; Ribaudo HJ; Dube MP; Murphy R; Yang OO; Currier JS; McComsey GA
Clin Infect Dis; 2015 Aug; 61(4):651-60. PubMed ID: 25904376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
